

File reference	W17FOI268
Key words	Multiple Sclerosis drug use
Date of release	21/08/2017
Attachments	Yes - L3

Freedom of Information Act Disclosure log - Reply Extract

You asked

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide.

Please provide the number of patients by treatment for the following disease modifying drugs.

Please provide the number of patients by treatment for the following disease modifying drugs.

Aubagio (teriflunomide)
 Avonex (interferon beta-1a)
 Betaferon (interferon beta-1b)
 Copaxone (glatiramer acetate)
 Extavia (beta interferon-1b)
 Gilenya (fingolimod)
 Lemtrada (alemtuzumab)
 Rebif (beta interferon-1a)
 Tecfidera (dimethyl fumarate)
 Tysabri (natalizumab)
 Ampyra (Fampyra)
 Peginterferon beta-1a (Plegridy)
 Daclizumab (Zinbryta)
 Ocrevus (Ocrelizumab)
 Others

Our response

The Trust is providing data for the period 01/01/17 to 30/06/17.

Medication	<p>The number of patients with Multiple Sclerosis have been treated with</p> <p>MS disease modifying drugs in the past 6 months, latest 6 months that you can provide.</p>
------------	--

Aubagio (teriflunomide)	Five or fewer
Avonex (interferon beta-1a)	15
Betaferon (interferon beta-1b)	Five or fewer
Copaxone (glatiramer acetate)	16
Extavia (beta interferon-1b)	Five or fewer
Gilenya (fingolimod)	24
Lemtrada (alemtuzumab)	32
Rebif (beta interferon-1a)	35
Tecfidera (dimethyl fumarate)	83
Tysabri (natalizumab)	35
Ampyra (Fampyra)	Five or fewer
Peginterferon beta-1a (Plegridy)	8
Daclizumab (Zinbryta)	0
Ocrevus (Ocrelizumab)	0
Others	N/A

Legal notes

Plymouth Hospitals NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. This avoids a breach of the first two Data Protection Act principles. This is in accordance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i), the personal information exemption as described in the Freedom of Information Act. A detailed rationale is provided in the attached document L3.